Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER

British Journal of Cancer

Volumn 110, Issue 11, 2014, Pages 2756-2764

  Yardley, D A ^a   Tripathy, D ^b   Brufsky, A M ^c   Rugo, H S ^d   Kaufman, P A ^e   Mayer, M ^f   Magidson, J ^g   Yoo, B ^h   Quah, C ^h   Ulcickas Yood, M ^i,j  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^f AdvancedBCorg 250 ^*  (United States)

^g Statistical Innovations   (United States)

^h GENENTECH INC   (United States)

ⁱ EpiSource LLC   (United States)

^j BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

HER2 positive; latent class modelling (LCM); long term survivors; metastatic breast cancer; registHER; short term survivors

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LAPATINIB; PROGESTERONE RECEPTOR; SERUM ALBUMIN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER SURVIVOR; CAUCASIAN; CLINICAL FEATURE; DEMOGRAPHY; FEMALE; HEART LEFT VENTRICLE FAILURE; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SHORT TERM SURVIVAL; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OBSERVATIONAL STUDY AS TOPIC; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; REGISTRIES; SURVIVORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84901617395     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.174     Document Type: Article

References (53)

1. Amend K, Hicks D, Ambrosone CB (2006) Breast cancer in African-American women: Differences in tumor biology from European-American Women. Cancer Res 66: 8327-8330.
2. Awada A, Bozovic-Spasojevic I, Chow L (2012) New therapies in HER2-positive breast cancer: a major step towards a cure of the disease? Cancer Treat Rev 38: 494-504.
3. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM. CLEOPATRA Study Group (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366: 109-119.
4. Bravo Marques JM (2009) Treatment of brain metastases in patients with HER2\+ breast cancer. Adv Ther 26(suppl 1): S18-S26.
5. Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, Tudor IC, Wang LI, Brammer MG, Shing M, Yood MU, Yardley DA (2011) Central nervous system metastases in patients with HER2-positive patients from registHER metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res 17: 4834-4843.
6. Brunetto AT, Sarker D, Papadatos-Pastos D, Fehrmann R, Kaye SB, Johnston S, Allen M, De Bono JS, Swanton C (2010) A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit. Br J Cancer 103: 607-612.
7. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295: 2492-2502.
8. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648.
9. Dawood S, Broglio K, Buzdar AU, Hortobágyi GN, Giordano SH (2010a) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 28: 92-98.
10. Dawood S, Broglio K, Ensor J, Hortobágyi GN, Giordano SH (2010b) Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol 21: 2169-2174.
11. Du XL, Lin CC, Johnson NJ, Altekruse S (2011) Effects of individual-level socioeconomic factors on racial disparities in cancer treatment and survival: findings from the National Longitudinal Mortality Study, 1979-2003. Cancer 117: 3242-3251.
12. Eroles P, Bosch A, Perez-Fidalgo JA, Lluch A (2012) Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treat Rev 38: 698-707.
13. Esteva FJ, Yu D, Hung MC, Hortobágyi GN (2010) Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol 7: 98-107.
14. Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey JR, Abdulkarim B (2006) Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 24: 5658-5663.
15. Gajria D, Chandarlapaty S (2011) HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther 11: 263-275.
16. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733-2743.
17. Goodman LA (1974) Exploratory latent structure analysis using both identifiable and unidentifiable models. Biometrika 61: 215-231.
18. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU (1996) Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14: 2197-2205.
19. Jensen JD, Knoop A, Laenkholm AV, Grauslund M, Jensen MB, Santoni-Rugiu E, Andersson M, Ewertz M (2012) PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann Oncol 23: 2034-2042.
20. Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ (1991) Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49: 650-655.
21. Kaufman PA, Brufsky AM, Mayer M, Rugo HS, Tripathy D, Yood MU, Feng S, Wang LI, Quah CS, Yardley DA (2012) Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. Breast Cancer Res Treat 135: 875-883.
22. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28: 3271-3277.
23. Kobayashi T, Ichiba T, Sakuyama T, Arakawa Y, Nagasaki E, Aiba K, Nogi H, Kawase K, Takeyama H, Toriumi Y, Uchida K, Kobayashi M, Kanehira C, Suzuki M, Ando N, Natori K, Kuraishi Y (2012) Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review. Breast Cancer 19: 218-237.
24. Largillier R, Ferrero J-M, Doyen J, Barriere M, Namer M, Mari V, Courdi A, Hannoun-Levi JM, Ettore F, Birtwisle-Peyrottes C, Balu-Maestro C, Marcy PY, Raoust I, Lallement M, Chamorey E (2008) Prognostic factors in 1038 women with metastatic breast cancer. Ann Oncol 19: 2012-2019.
25. Leyland-Jones B (2009) Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 27: 5278-5286.
26. Lis CG, Grutsch JF, Vashi PG, Lammersfeld CA (2003) Is serum albumin an independent predictor of survival in patients with breast cancer? J Parenter Enteral Nutr 27: 10-15.
27. Liu AN, Sun P, Liu JN, Ma JB, Qu HJ, Zhu H, Yu CY, Zhang LM (2012) Clinicopathologic characteristics and prognostic factors in patients with operable HER-2 overexpressing breast cancer. Asian Pac J Cancer Prev 13: 1197-1201.
28. National Cancer Institute (2006) Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available at http://ctep.cancer.gov/protocolDevelopment/ electronic-applications/docs/ctcaev3.pdf. Accessed 18 April 2013.
29. Newman LA (2005) Breast cancer in African-American women. Oncologist 10(1): 1-14.
30. Ooi SL, Martinez ME, Li CI (2011) Disparities in breast cancer characteristics and outcomes by race/ethnicity. Breast Cancer Res Treat 127: 729-738.
31. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN (2009) Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 7: 4-13.
32. Olson EM, Najita JS, Sohl J, Arnaout A, Burstein HJ, Winer EP, Lin NU (2013) Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast 22: 525-531.
33. Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, Crivellari D, Fey MF, Murray E, Pagani O, Simoncini E, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A. International Breast Cancer Study Group (IBCSG) (2006) Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 17: 935-944.
34. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD. Herceptin Adjuvant (HERA) Trial Study Team (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659-1672.
35. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer Jr CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684.
36. Romond E, Suman VJ, Jeong J-H, Sledge Jr GW, Geyer Jr CE, Martino S, Rastogi P, Gralow J, Swain SM, Winer E, Colon-Otero G, Hudis C, Paik S, Davidson N, Mamounas EP, Zujewski JA, Wolmark N, Perez EA. National Surgical Adjuvant Breast and Bowel Project (NSABP) Operations and Biostatistical Centers (2012) Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831. Cancer Res 72(suppl 3): abstr S5-abstr S5.
37. Ross R, Galsky M, Scher H, Magidson J, Wassmann K, Lee G, Katz L, Subudhi S, Anand A, Fleisher M, Kantoff P, Oh W (2012) A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol 13: 1105-1113.
38. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobágyi GN (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14: 320-368.
39. Rugo HS, Brufsky AM, Yood MU, Tripathy D, Kaufman PA, Mayer M, Yoo B, Abidoye OO, Yardley DA (2013) Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat 141: 461-470.
40. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30.
41. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182.
42. Slamon D, EiermannW, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J. Breast Cancer International Research Group (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365: 1273-1283.
43. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792.
44. Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge Jr GW, Wood WC, Davidson NE (2012) Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. J Natl Cancer Inst 104: 1-9.
45. Sperinde J, Jin X, Banerjee J, Penuel E, Saha A, Diedrich G, Huang W, Leitzel K, Weidler J, Ali SM, Fuchs EM, Singer CF, Köstler WJ, Bates M, Parry G, Winslow J, Lipton A (2010) Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients. Clin Cancer Res 16: 4226-4235.
46. Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14: 461-471.
47. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K. EMILIA Study Group (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367: 1783-1791 (Erratum in N Engl J Med 2013; 368: 2442).
48. Vermunt JK (2009) Event history analysis. In: Handbook of Quantitative Methods in Psychology, Millsap R, Maydeu-Olivares A (eds), pp 658-674. Sage: London, UK.
49. Vermunt JK (2010) Latent class modeling with covariates: two improved three-step approaches. Political Anal 18, 450-469.
50. Vermunt JK, Magidson J (2000) Latent GOLD User's Guide. Statistical Innovations Inc.: Boston, MA, USA.
51. Yardley DA, Kaufman PA, Brufsky A, Ulcickas Yood M, Rugo H, Mayer M, Quah C, Yoo B, Tripathy D (2014) Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. Breast Cancer Res Treat; e-pub ahead of print 6 April 2014; doi:10.1007/s10549- 014-2916-8.
52. Yardley DA, Tripathy D, Brufsky AM, Rugo HS, Kaufman PA, Mayer M, Feng S, Abidoye O, Ulcickas Yood M (2012) Long-term survivor characteristics in HER2-positive metastatic breast cancer. J Clin Oncol 30(suppl 27): abstr 133.
53. Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A (2005) Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 93: 552-556.